Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib

A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.

Influência do alquil benzeno sulfonato de sódio a 11 por cento na adaptaçäo de dois revestimentos sobre uma cera para fundiçäo / Wetting effects of alky benzene sodium sulphonate at 11 per cents on inlay wax-investments combinations

Verificou-se o efeito do tratamento superficial do modelo de cera com o alquil benzeno sulfonato de sódio a 11 por cento na adaptaçäo de 2 revestimentos, um à base de cristobalita e outro, de quartzo. O método utilizado foi o da mensuraçäo do ângulo de contacto formado entre a cera e os revestimentos, estando a superfície da cera antes da inclusäo, tratada com detergente e deixada molhada, e, tratada, porém seca. O ângulo formado foi avaliado através de um microscópio de mensuraçäo Carl Zeiss com dispositivo apropriado. Verificou-se que o alquil benzeno sulfonato de sódio a 11 por cento, melhora a adaptaçäo do revestimento à base de quartzo, porém näo interfere na do revestimento à base de cristobalita, e que näo há superioridade de um método de tratamento sobre o outro, isto é, estando a superfície da cera molhada ou seca

Drug trial of Schistosoma japonicum enfection in Indonesia.

A limited drug trial was carried out on 42 cases with schistosomiasis japonica from an endemic area of Central Sulawesi. The drugs used were niridazole and stibophen. The effects of treatment were reported and discussed. The results of this study offer promise for treating S. japonicum infection in Central Sulawesi on a larger scale.

Current chemotherapy of schistosomiasis japonica in the Philippines.

For the past several decades, the drug being used for the treatment of schistosomiasis in the Philippines has been Stibophen. It is administered intramuscularly at a dose of 1 ml per 10 kg body weight with a maximum of 5 ml every other day after 2 initial daily smaller sensitivity doses at a total dose of 45 to 70 ml fof adult patients. In recent years, a number of drugs for the treatment of schistosomiasis have been developed. These were evaluated clinically either in the hospital or in field trials in Leyte. Unfortunately, none of these were found to be suitable for mass treatment on account of toxicity to prolonged course of treatment. In view of the pressing need for a safe and effective schistosomicidal agent, the search for a better drug is imperative.